

September 16, 2022

Company name: Takara Bio Inc.
Name of Representative: Koichi Nakao, President & CEO
(Securities code: 4974; TSE Prime)
Inquiries: Takuya Kakemi, Executive Officer,
Head of Corporate Management
Division
(Telephone: +81-775-565-6970)

[Correction]
Annual Securities Report for the Fiscal Year Ended March 31, 2022

Takara Bio Inc. hereby announces that there have been corrections made to the above-mentioned disclosure material released on August 29, 2022, at 5:15 pm. (JST).

1. Reason for corrections

The correction is due to the confirmation of errors in the stated items on the “Annual Securities Report for the Fiscal Year Ended March 31, 2022”.

2. Details of corrections

Page 50. “4) Assistant accountants who participated in audits”

| Before correction | After correction |
|---|---|
| <u>Ten</u> certified public accountants and <u>ten</u> others | <u>Nine</u> certified public accountants and <u>eleven</u> others |

* Corrections are underlined.